Risk Reduction for Alzheimer's Disease

PHASE2/PHASE3CompletedINTERVENTIONAL
Enrollment

513

Participants

Timeline

Start Date

February 2, 2017

Primary Completion Date

November 30, 2021

Study Completion Date

January 31, 2022

Conditions
Cognitively Normal Older AdultsHypertensionSubjective Cognitive DeclineFamily History of Alzheimer's Disease
Interventions
DRUG

Angiotensin II receptor blocker (ARB, losartan) and calcium channel blocker (CCB, amlodipine)

"Angiotensin II receptor blocker (ARB, losartan) and calcium channel blocker (CCB, amlodipine) will be used to reduce SBP\<130 mmHg; atorvastatin 80 mg daily will be administered to reduce blood lipid level. Additional antihypertensives may be used if needed.~Intensive Reduction of Vascular Risk Factors (IRVR)"

BEHAVIORAL

Aerobic Exercise Training

Participants will take part in a supervised, moderate to vigorous aerobic exercise training program for approximately 24 months. This program consists of exercising 3 times per week for about 30 minutes per session at the beginning, and will increase to 4-5 times per week, 40-50 minutes per session over a period of 4-5 months. Exercise frequency, intensity and duration will be maintained at this level during the rest of the study period.

OTHER

Usual Care

Participants will follow their regular doctor's recommendations for blood pressure and lipid control.

BEHAVIORAL

Stretching Exercise

Participants will perform home-based stretching exercise 3 times per week, gradually increased to 4-5 times per week over a period of 4-5 months, and maintained at this level during the rest of the study period. They will be encouraged to attend monthly stretching exercise classes, which will be led by study staff or exercise trainers.

Trial Locations (4)

63110

Washington University in St. Louis, St Louis

66160

University of Kansas Medical Center Research Institute, Kansas City

70808

Pennington Biomedical Research Center, Baton Rouge

75390

UT Southwestern Medical Center, Dallas

All Listed Sponsors
collaborator

Texas Health Resources

OTHER

collaborator

University of Kansas Medical Center

OTHER

collaborator

Washington University School of Medicine

OTHER

collaborator

Pennington Biomedical Research Center

OTHER

collaborator

Michigan State University

OTHER

lead

University of Texas Southwestern Medical Center

OTHER

NCT02913664 - Risk Reduction for Alzheimer's Disease | Biotech Hunter | Biotech Hunter